Back to News
Market Impact: 0.35

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

EDIT
Corporate EarningsHealthcare & BiotechCompany FundamentalsAnalyst Estimates

Editas reported a quarterly EPS loss of $0.06 versus the Zacks consensus loss of $0.27, beating estimates by $0.21 and improving from a $0.55 loss a year earlier. The materially narrower loss year-over-year and versus consensus is a modest positive for the stock, though no guidance was provided so the print is unlikely to drive large sector moves.

Analysis

Editas reported a quarterly EPS loss of $0.06 versus the Zacks consensus loss of $0.27, beating estimates by $0.21 and improving from a $0.55 loss a year earlier. The materially narrower loss year-over-year and versus consensus is a modest positive for the stock, though no guidance was provided so the print is unlikely to drive large sector moves.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.35

Ticker Sentiment

EDIT0.35